CAC
AVDL

Cowen and Company’s Avadel Pharmaceuticals AVDL Stock Holding History

Cowen and Company’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,642,347
Closed -$23.2M – 676
2023
Q4 		$23.2M Sell
1,642,347
-695,955
-30% -$8.18M 1.52% 19
2023
Q3 		$24.1M Sell
2,338,302
-325,774
-12% -$4.36M 1.69% 12
2023
Q2 		$43.9M Sell
2,664,076
-1,068,702
-29% -$13.9M 3.64% 6
2023
Q1 		$34.2M Hold
3,732,778
– – 4.02% 4
2022
Q4 		$26.7M Hold
3,732,778
– – 2.79% 11
2022
Q3 		$18.7M Hold
3,732,778
– – 1.79% 18
2022
Q2 		$9.11M Hold
3,732,778
– – 0.88% 28
2022
Q1 		$25.5M Hold
3,732,778
– – 2.45% 12
2021
Q4 		$30.2M Buy
3,732,778
+1,207,326
+48% +$11M 2.74% 7
2021
Q3 		$24.7M Buy
2,525,452
+29,879
+1% +$235K 1.17% 18
2021
Q2 		$16.8M Hold
2,495,573
– – 0.88% 18
2021
Q1 		$22.6M Buy
2,495,573
+603,530
+32% +$4.88M 1.55% 11
2020
Q4 		$12.6M Sell
1,892,043
-13,947
-0.7% -$87.2K 1.13% 14
2020
Q3 		$9.61M Sell
1,905,990
-1,514
-0.1% -$11K 1.57% 10
2020
Q2 		$15.4M Buy
1,907,504
+390,208
+26% +$3.44M 2.56% 6
2020
Q1 		$10.8M Buy
+1,517,296
New +$11.7M 2.47% 7

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cowen and Company's AVDL Position: Q1 2024 in Review

Cowen and Company sold out of Avadel Pharmaceuticals (AVDL) in Q1 2024, closing a stake of 1,642,347 shares — an estimated $23.2M sold.

Cowen and Company first reported a position in AVDL in Q1 2020 and held it in 16 quarters. The position peaked at $43.9M in Q2 2023. 127 funds tracked by Wall St. Rank hold AVDL as of Q1 2024.

  • Cowen and Company reported no remaining Avadel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 1,642,347 Avadel Pharmaceuticals shares in Q1 2024, an estimated $23.2M.
  • Cowen and Company first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 16 quarters.
  • Cowen and Company's Avadel Pharmaceuticals position peaked at $43.9M in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.